Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma
The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.
The American Journal of Managed Care2 天
To Improve Clinical Trial Equity in Multiple Myeloma, Just Ask
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
SDxCentral3 天
Johnson & Johnson Gets Health Canada Approval for CARVYKTI® Therapy
Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...
The American Journal of Managed Care5 天
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...
Cure Today6 天
Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...